7,12-Dimethylbenz[a]anthracene (Synonyms: DMBA) |
Catalog No.GC46733 |
7,12-Dimethylbenz[a]anthracene는 면역억제제이자 강력한 장기특이성 발암물질이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 57-97-6
Sample solution is provided at 25 µL, 10mM.
7,12-Dimethylbenz[a]anthracene는 면역억제제이자 강력한 장기특이성 발암물질이다. 7,12-Dimethylbenz[a]anthracene와 12-O-tetradecanoylphorbol-13-acetate (TPA)를 함께 치료하면 일부 두단계 발암모형에서 종양성장을 촉진한다[1].
7,12-Dimethylbenz[a]anthracene (1μM; 4시간)은 NHKCs에서 CCL20, IL-36γ, p19의 표현을 증가시켰다[2]. 7,12-Dimethylbenz[a]anthracene (20μM; 24시간과 44시간)은 24시간에 난소양성세포의 확장을 억제하고 44시간에 난소양성세포와 알류의 분리 과정을 촉진하고ROS가 급격히 상승을 유도한다[3].
7,12-Dimethylbenz[a]anthracene (1mg/kg; 구강 투여; 6주) 노출은 전암성 유방조직에서 EGFR, ErbB2, Akt, Erk의 활성을 강화시켰다[4]. 7,12-Dimethylbenz[a]anthracene (20μg/ml; 24시간) 처리 후 MCF10A 세포에서 E-CAD의 표현이 감소하고 α-SMA의 표현이 증가했다[5]. 7,12-Dimethylbenz[a]anthracene (50mg/kg; 구강 투여; 4주)는 종양에서 PGE2 수준을 증가시켰다[6].
References:
[1].Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res. 2005 Oct 15;65(20):9304-11.
[2].Sato Y, Fujimura T, Hidaka T, Lyu C, Tanita K, Matsushita S, Yamamoto M, Aiba S. Possible Roles of Proinflammatory Signaling in Keratinocytes Through Aryl Hydrocarbon Receptor Ligands for the Development of Squamous Cell Carcinoma. Front Immunol. 2020 Oct 16;11:534323
[3].Song ZQ, Li X, Wang YK, Du ZQ, Yang CX. 7,12-DIMETHYLBENZ[Α]ANTHRACENE acts on cumulus cells to desynchronize nuclear and cytoplasmic maturation of pig oocytes. Sci Rep. 2017 May 10;7(1):1687.
[4].Ma Z, Kim YM, Howard EW, Feng X, Kosanke SD, Yang S, Jiang Y, Parris AB, Cao X, Li S, Yang X. 7,12-DIMETHYLBENZ[Α]ANTHRACENE promotes ErbB2 mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability. Oncol Rep. 2018 Sep;40(3):1632-1640.
[5].Liu G, Lim D, Cai Z, Ding W, Tian Z, Dong C, Zhang F, Guo G, Wang X, Zhou P, Feng Z. The Valproate Mediates Radio-Bidirectional Regulation Through RFWD3-Dependent Ubiquitination on Rad51. Front Oncol. 2021 Mar 25;11:646256.
[6].Karimi B, Ashrafi M, Shomali T, Yektaseresht A. Therapeutic effect of simvastatin on 7,12-DIMETHYLBENZ[Α]ANTHRACENE-induced breast cancer in mice. Fundam Clin Pharmacol. 2019 Feb;33(1):84-93.
세포 실험 [1]: | |
세포 라인 | 정상적인 인간 표피 각질세포 |
제조 방법 | 정상적인 인간 표피 각질세포는 7,12-Dimethylbenz[a]anthracene 1μM으로 4시간 동안 처리되었습니다. |
반응 조건 | 7,12-Dimethylbenz[a]anthracene:1μM; 4시간 동안 |
응용 분야 | 7,12-Dimethylbenz[a]anthracene는 CYP1A1뿐만 아니라 CCL20, p19, IL-36γ mRNA의 표현을 증가시켰습니다. p40와 IL-36β mRNA의 표현에는 현저한 증가가 없었습니다. |
동물 실험 [2]: | |
동물 모형 | 유선 종양 모델 |
제조 방법 | 모든 실험은 암컷 스프레이그-다우리얼 쥐를 사용하여 수행되었습니다. 이 동물들은 50일령에 140-150그람의 몸무게를 가졌고 탄화물 식이를 먹고 호흡기질환이 없는 상태였습니다. 7,12-Dimethylbenz[a]anthracene (DMBA) 2그램을 참기름 100ml에 녹이고 살짝 데웠습니다. 그 용액은 소프트 실리콘 캐서터를 통해 위로 드리워지고 투여는 단 한 번만 이루어졌습니다. |
제형 | 7,12-Dimethylbenz[a]anthracene: 15, 20mg/each; po;1 번 |
응용 분야 | 7,12-Dimethylbenz[a]anthracene를 먹인 쥐는 150일 내에 종양이 검출되었고 성 주기가 4-15일마다 발생했습니다. 7,12-Dimethylbenz[a]anthracene는 암과 백혈구감소를 유발하고 일시적인 신체 성장을 중단시켰고 뇌하수체 성선호르몬 생산이나 자궁 기능에 현저한 감소를 일으키지 않았습니다. |
References: |
Cas No. | 57-97-6 | SDF | |
Synonyms | DMBA | ||
Canonical SMILES | CC1=C2C=CC=CC2=C(C)C3=C4C(C=CC=C4)=CC=C13 | ||
Formula | C20H16 | M.Wt | 256.3 |
Solubility | DMF: 20 mg/ml,DMSO: 10 mg/ml | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 3.9017 mL | 19.5084 mL | 39.0168 mL |
5 mM | 0.7803 mL | 3.9017 mL | 7.8034 mL |
10 mM | 0.3902 mL | 1.9508 mL | 3.9017 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 32 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *